Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: A prospective study of 22 patients.

In patients with early stage initial aPD, s substantial benefit of APO was observed on motor symptoms, driven by a 70% reduction in -time versus baseline, superior to that observed in previous prospective studies. APO also improved frontal dysfunction in PD patients.